CLEVELAND, Ohio — A genomic test used to assess prostate cancer risk may also help doctors determine which patients are ...

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

An NRG Oncology SPPORT trial analysis found that Luminal B prostate tumors identified by the PAM50 genomic classifier predicted a much larger benefit from adding short-term hormone therapy to salvage ...

Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. "Our ...

Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit ...

Please provide your email address to receive an email when new articles are posted on . Use of a precision navigator led to significant increase in genomic profiling among men with prostate cancer.

Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysisSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. ( ...

The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and ...

Abbott introduces whole-genome sequencing Oncodetect MRD test to detect traces of cancer during and after treatment: Abbott Park, Illinois Wednesday, October 28, 2026, 16:00 Hrs [ ...